Belančić, A.; Strbad, T.; Kučan Štiglić, M.; Vitezić, D. Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety. Journal of Personalized Medicine 2024, 14, 244, doi:10.3390/jpm14030244.
Belančić, A.; Strbad, T.; Kučan Štiglić, M.; Vitezić, D. Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety. Journal of Personalized Medicine 2024, 14, 244, doi:10.3390/jpm14030244.
Belančić, A.; Strbad, T.; Kučan Štiglić, M.; Vitezić, D. Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety. Journal of Personalized Medicine 2024, 14, 244, doi:10.3390/jpm14030244.
Belančić, A.; Strbad, T.; Kučan Štiglić, M.; Vitezić, D. Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety. Journal of Personalized Medicine 2024, 14, 244, doi:10.3390/jpm14030244.
Abstract
(1) Background: Aim was to investigate real-world effectiveness (hypothesizing non-inferiority) and safety profile of risdiplam in paediatric and adult nusinersen-risdiplam spinal muscular atrophy (SMA) switch cohort. (2) Methods: A retrospective and anonymous collection of relevant demographic and clinical data for all Croatian SMA patients switched from nusinersen to risdiplam up to September 2023 (reimbursed by Croatian Health Insurance Fund – CHIF) was performed using CHIF database and associated reimbursement documentation. Patients were included in effectiveness and safety analysis if they met the following inclusion criteria: i) risdiplam reimbursed by CHIF; ii) patient received at least 6 doses of nusinersen before switch to risdiplam; iii) no relevant pause between the latter disease modifying drugs (DMDs); iv) availability of all prespecified studied data and parameters. (3) Results: 17 patients met inclusion criteria [58.9% female; median age 12.75 (3.0-44.5) yr.]. In our ‘switch’ cohort, we have demonstrated a non-inferiority of risdiplam to nusinersen, in SMA 1 (+1.0 in CHOP INTEND; p=0.067), SMA 3p (+0.7 in HFMSE; p=0.897) and SMA 3a (+0.8 in RHS; p=0.463) subpopulations, during a one-year follow-up period. There were no reports on respiratory function worsening, feeding worsening, and no lethal events. No new safety concerns were identified, except of the weight gain that arose as a new potential adverse drug reaction ‘signal’ in two patients. (4) Conclusions: We have reported a pivotal real-world findings on switching SMA patients from nusinersen to risdiplam and demonstrated its effectiveness (non-inferiority), safety and tolerability in a heterogenous paediatric and adult ‘switch’ cohort, which will further increase the quality and standards of care as well as safety of a notable portion of SMA patients; especially for those who demand switch from nusinersen to other DMDs from clinical or personal reasons.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
